EPISODE · May 15, 2025 · 21 MIN
Treatment of Metastatic Non-Small Cell Lung Cancer With Targeted Mutations
from Oncology Brothers: Practice-Changing Cancer Discussions · host Oncology Brothers
Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for metastatic non-small cell lung cancer (NSCLC) with actionable mutations in frontline therapy. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Susan Scott, a thoracic medical oncologist from the Johns Hopkins Hospital.In this episode, we covered:• Common EGFR mutations and the latest treatment options, including osimertinib, amivantamab, and chemotherapy combinations.• The importance of comprehensive NGS testing and the need for retesting at progression.• Insights into managing side effects associated with various therapies, including the proactive management of cutaneous toxicities.• Treatment strategies for less common mutations such as ALK, ROS1, BRAF, and RET, along with their respective targeted therapies.• The role of immunotherapy in specific mutations and the importance of patient choice and preferences in treatment decisions.Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice.YouTube: https://youtu.be/LMYDAjZcn5wFollow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
What this episode covers
Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for metastatic non-small cell lung cancer (NSCLC) with actionable mutations in frontline therapy. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Susan Scott, a thoracic medical oncologist from the Johns Hopkins Hospital.In this episode, we covered:• Common EGFR mutations and the latest treatment options, including osimertinib, amivantamab, and chemotherapy combinations.• The importance of comprehensive NGS testing and the need for retesting at progression.• Insights into managing side effects associated with various therapies, including the proactive management of cutaneous toxicities.• Treatment strategies for less common mutations such as ALK, ROS1, BRAF, and RET, along with their respective targeted therapies.• The role of immunotherapy in specific mutations and the importance of patient choice and preferences in treatment decisions.Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice.YouTube: https://youtu.be/LMYDAjZcn5wFollow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
NOW PLAYING
Treatment of Metastatic Non-Small Cell Lung Cancer With Targeted Mutations
No transcript for this episode yet
Similar Episodes
Mar 31, 2026 ·54m
Mar 27, 2026 ·14m
Mar 24, 2026 ·42m
Mar 20, 2026 ·42m
Mar 17, 2026 ·41m
Mar 13, 2026 ·44m